# Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

> **NCT01243177** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES GmbH** · enrollment: 888 (actual)

## Conditions studied

- Epilepsy
- Monotherapy

## Interventions

- **DRUG:** Lacosamide
- **DRUG:** Carbamazepine-Controlled Release

## Key facts

- **NCT ID:** NCT01243177
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 888 (ACTUAL)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243177, "Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01243177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*